Healthcare Industry News: Allergan
News Release - December 18, 2017
Allergan Announces Promotion of Wayne Swanton to Executive Vice President, Global OperationsSwanton to Join Allergan Executive Leadership Team Following Departure of Rob Stewart, Executive Vice President and Chief Operating Officer
DUBLIN, Dec. 18, 2017 -- (Healthcare Sales & Marketing Network) -- Allergan plc (NYSE: AGN) a leading global biopharmaceutical company, today announced that Wayne Swanton has been promoted to Executive Vice President, Global Operations following notification that Rob Stewart, Executive Vice President and Chief Operating Officer, intends to leave Allergan to become President and CEO of Amneal Pharmaceuticals in 2018. Wayne Swanton will join Allergan's Executive Leadership Team and maintain responsibility for Global Manufacturing, Quality, Supply Chain, Procurement, Pharmaceutical Technology, Operational Excellence, Engineering, Environmental Health & Safety and Security.
"Wayne Swanton has led our global operations team during a period of rapid change, including the acquisition of Forest Labs and Allergan, as well as the divestiture of our global generics business. Through all of those changes, Wayne's team has maintained high-quality standards, dramatically increased efficiency of our manufacturing operations and supply chain through operational excellence, improved on-time delivery of products to customers, provided increased value across Allergan through our procurement team while driving an industry leading environmental health & safety culture," said Brent Saunders, Chairman and Chief Executive Officer.
"Rob Stewart has been a key part of the transformation of our company from a generic manufacturer to a leading branded pharmaceutical innovator over the past eight years. During his time, he helped streamline manufacturing, enhance operational excellence, and played an instrumental role in integrating many companies into Allergan. Our focus on succession planning and Rob's leadership in developing a strong bench has enabled us to have a smooth transition of his responsibilities. I thank Rob for his contributions and wish him success on his next career opportunity," added Saunders.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry with 65+ mid-to-late stage pipeline programs currently in development.
Allergan's success is powered by our more than 18,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan's website at www.Allergan.com.
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016 and Allergan's Quarterly Report on Form 10-Q for the period ended September 30, 2017. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsAllergan Announces FDA Approval of AVYCAZ(R) (ceftazidime and avibactam) for Pediatric Patients
Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine
FDA Accepts Supplemental Biologics License Applications (sBLAs) for BOTOX(R) (onabotulinumtoxinA) for Pediatric Patients with Upper and Lower Limb Spasticity